Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Translational Development Acquisition (TDAC) Net Income towards Common Stockholders (2024 - 2026)

Translational Development Acquisition's Net Income towards Common Stockholders history spans 3 years, with the latest figure at $283351.0 for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 75.74% to $283351.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$464884.0, a 139.97% decrease, with the full-year FY2025 number at $1.4 million, up 28824.61% from a year prior.
  • Net Income towards Common Stockholders came in at $283351.0 for Q1 2026, up from -$2.4 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $1.3 million in Q3 2025, with the low at -$2.4 million in Q4 2025.
  • Historically, Net Income towards Common Stockholders has averaged $87272.8 across 3 years, with a median of $170805.0 in 2024.
  • Peak annual rise in Net Income towards Common Stockholders hit 20581.9% in 2025, while the deepest fall reached 4220.46% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $58259.0 in 2024, then crashed by 4220.46% to -$2.4 million in 2025, then soared by 111.8% to $283351.0 in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for TDAC at $283351.0 in Q1 2026, -$2.4 million in Q4 2025, and $1.3 million in Q3 2025.